Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzem NCD Alone or with Sunitinib in Metastatic Renal Cell Carcinoma
NCT00444314Phase 2Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Feb 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Panzem in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by CASI Pharmaceuticals, Inc. Primary endpoint: Objective Response Rate. Started Feb 2007; status: completed.
02
Drugs
Panzem
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00444314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444314.